Skip to content

Skin Manifestations Associated With Adhesives in Diabetes Technology Tools

CUTADIAB OBSERVATORY Investigation of the Skin Manifestations Associated With the Adhesives of Technological Tools for Diabetes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04853810
Acronym
CUTADIAB
Enrollment
851
Registered
2021-04-21
Start date
2021-05-17
Completion date
2021-11-17
Last updated
2024-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The use of technological tools in the treatment of diabetes has intensified and become common in recent years. Many of these systems adhere to the skin with an adhesive in place between 2 and 14 days. The objective of this study is to determine the prevalence and consequences of skin reactions to skin adhesive systems for the treatment of diabetes.

Detailed description

The use of technological tools in the treatment of diabetes has intensified and become common in recent years. Many of these systems adhere to the skin with an adhesive in place for between 2 and 14 days, or even longer, depending on the system under consideration. Unfortunately, an increase in skin reactions has been observed in diabetic patients using these new technologies, sometimes leading to discontinuation. The number of studies evaluating the cutaneous tolerance of the patches used by these technologies is limited, so the prevalence of these skin intolerances is unknown. The objective of this study is to determine the prevalence and consequences of skin reactions to skin adhesive systems for the treatment of diabetes. It will be implemented with the following design: * observational, cross-sectional, multicentre study involving 4 Diabetology centres and over a period of 6 months. * Establishment of an observatory on skin reactions to FreeStyle Libre® (FSL) and all other adhesive systems related to new technologies for the treatment of diabetes * A questionnaire will be systematically proposed to the patients concerned, during the usual diabetes follow-up consultations made by all investigators.

Interventions

OTHERCUTADIAB questionnaire

During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and Women * Adult (≥ 18 years old) * All types diabetes (1, 2, other) * Any patient who wears or has worn an adhesive system for the treatment of diabetes (insulin pump, and/or continuous glucose monitoring system) within the last 10 years. * Seen consecutively in consultation * Patient who was informed on the research and are not opposed to participation.

Exclusion criteria

* Illiteracy * Refusal to participate in the study (refusals will be counted) * Patient under guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
Percentage of skin intolerance to adhesives in diabetic patientsSingle visit at day 0Percentage of skin intolerance in diabetic patients - all types of diabetes - using or having used in the last 10 years adhesive systems integrated into diabetes medical devices: patch insulin pump, pump with externalized catheter or continuous glucose measurement system.

Secondary

MeasureTime frameDescription
Consequences of skin reactionsSingle visit at day 0Consequences of skin reactions (continuation / compliance / stopping / stopping then resuming and a delay time before resuming)
Percentage of positive responses to the question concerning patient approaches to avoid skin reactionSingle visit at day 0The patient is asked to answer the question Do you use or have you used any tips to avoid or treat these skin manifestations by choosing between the responses provided below (several possible items): * no * cortisone ointment on removal from the system * name of the ointment used:… .. * other ointment when removing the system * name of the ointment used:… .. * adhesive between skin and system * name of the adhesive used * other protection between the skin and the system (ointment, spray, etc.) * name of the protection used * stop using product before installation * change of the installation location of the system with the same reaction * change of the installation location of the system with improvement * stop using product before installation
Prevalence of skin reactions by adhesive systemSingle visit at day 0Skin intolerance in diabetic patients - all types of diabetes combined - using or having used adhesive systems integrated in diabetes medical devices, depending on the systems used
Semiological description of skin lesionsSingle visit at day 0The patient is asked to describe his skin manifestations by choosing between the responses provided below (several possible items): * redness * change in skin color (other than redness) * vesicles (blisters) / bubbles * peeling (loss of small pieces of skin) * it itches * it hurts * it flows * redness or bubbles are strictly localized under the adhesive * redness or bubbles overflow from the adhesive * infection (abscess or other) requiring treatment * antibiotic therapy / surgery (several items possible) * other (in full):
Evolution of lesionsSingle visit at day 0The patient is asked to answer the question How long is the reaction present? by choosing between the responses provided below : * less than an hour * more than an hour and less than 24 hours * more than 24 hours and less than a week * more than a week and less than a month * more than a month * the reaction never went away
Percentage of positive responses to the question concerning the delay of appearance of skin manifestationSingle visit at day 0The patient is asked to answer the question what time passed between the first use of the pump and the first appearance of skin manifestations by choosing between the responses provided below: * from the 1st installation * less than a week * less than a month * between 1 and 2 months * between 2 and 6 months * more than 6 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026